Skip to main content

Drug Interactions between Periostat and vitamin a

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

doxycycline vitamin A

Applies to: Periostat (doxycycline) and vitamin a

MONITOR CLOSELY: Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign intracranial hypertension. These agents individually have been associated with the development of pseudotumor cerebri and may have additive effects during coadministration. The interaction has been suspected in reported cases involving the use of isotretinoin or vitamin A in combination with a tetracycline. Other vitamin A-related compounds may interact similarly. Both acute and chronic vitamin A intoxication have been identified as secondary causes of pseudotumor cerebri.

MANAGEMENT: Caution is advised if vitamin A is coadministered with tetracyclines. Concomitant use of most retinoids (vitamin A derivatives) with tetracyclines is considered contraindicated. Patients should be counseled to contact their healthcare provider immediately if they develop signs or symptoms of pseudotumor cerebri such as papilledema, headache, nausea, vomiting, and/or visual disturbances. The patient should be advised to discontinue vitamin A and the tetracycline and be referred for immediate neurological evaluation and care if pseudotumor cerebri is suspected as this could result in permanent vision loss.

References

  1. Walters BN, Gubbay SS (1981) "Tetracycline and benign intracranial hypertension: report of five cases." Br Med J, 282, p. 19-20
  2. Minutello JS, Dimayuga RG, Carter J (1988) "Pseudotumor cerebri, a rare adverse reaction to tetracycline therapy." J Periodontol, 59, p. 848-51
  3. Delaney RA, Narayanaswamy TR (1990) "Pseudo-tumor cerebri and acne." Mil Med, 155, p. 511
  4. Donnet A, Dufour H, Graziani N, Grisoli F (1992) "Minocycline and benign intracranial hypertension." Biomed Pharmacother, 46, p. 171-2
  5. (2001) "Product Information. Achromycin (tetracycline)." Lederle Laboratories
  6. Yokokura M, Hatake K, Komatsu N, Kajitani H, Miura Y (1994) "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet, 343, p. 361-2
  7. Schmitt K, Schwarz R, Tulzer G, Krieger O, Zoubek A, Gadner H (1994) "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet, 343, p. 361
  8. (2001) "Product Information. Accutane (isotretinoin)." Roche Laboratories
  9. Gardner K, Cox T, Digre KB (1995) "Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review." Neurology, 45, p. 6-10
  10. Cuddihy J (1994) "Case report of benign intercranial hypertension secondary to tetracycline." Ir Med J, 87, p. 90
  11. Lee AG (1995) "Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne." Cutis, 55, p. 165-8
  12. Roytman M, Frumkin A, Bohn TG (1988) "Pseudotumor cerebri caused by isotretinoin." Cutis, 42, p. 399-400
  13. Lewis PA, Kearney PJ (1997) "Pseudotumor cerebri induced by minocycline treatment for acne vulgaris." Acta Derm Venereol, 77, p. 83
  14. (2001) "Product Information. Soriatane (acitretin)." Roche Laboratories
  15. Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, Musson KH, Eggenberger ER (1998) "Minocycline treatment and pseudotumor cerebri syndrome." Am J Ophthalmol, 126, p. 116-21
  16. (2001) "Product Information. Vesanoid (tretinoin)." Roche Laboratories
  17. Weese-Mayer DE, Yang RJ, Mayer JR, Zaparackas Z (2001) "Minocycline and Pseudotumor cerebri: The well-known but well-kept secret." Pediatrics, 108, p. 519-20
  18. Moskowitz Y, Leibowitz E, Ronen M, Aviel E (1993) "Pseudotumor cerebri induced by vitamin A combined with minocycline." Ann Ophthalmol, 25, p. 306-8
  19. Chan AY, Liu DT, Friedman DI, Gordon LK, Egan RA (2005) "Doxycycline and intracranial hypertension." Neurology, 64, p. 765-6
  20. Tabibian JH, Gutierrez MA (2009) "Doxycycline-induced pseudotumor cerebri." South Med J, 102, p. 310-1
  21. (2018) "Product Information. Seysara (sarecycline)." Allergan Inc
  22. Gasparian S, Geng X, Hawy E (2021) "Intracranial hypertension associated with topical tretinoin use." Am J Ophthalmol Case Rep, 23, p. 101130
  23. Tor Generics Limited (2023) Retinol and colecalciferol 4500 IU/450 IU soft gel capsules (vitamin a & d). https://www.medicines.org.uk/emc/product/11767/smpc
View all 23 references

Switch to consumer interaction data

Drug and food interactions

Moderate

doxycycline food

Applies to: Periostat (doxycycline)

GENERALLY AVOID: The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the iron cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. In ten healthy volunteers, simultaneous oral administration of ferrous sulfate 200 mg and single doses of various tetracyclines (200 mg to 500 mg) resulted in reductions in the serum levels of methacycline and doxycycline by 80% to 90%, oxytetracycline by 50% to 60%, and tetracycline by 40% to 50%. In another study, 300 mg of ferrous sulfate reduced the absorption of tetracycline by 81% and that of minocycline by 77%. Conversely, the absorption of iron has been shown to be decreased by up to 78% in healthy subjects and up to 65% in patients with iron depletion when ferrous sulfate 250 mg was administered with tetracycline 500 mg. Available data suggest that administration of iron 3 hours before or 2 hours after a tetracycline largely prevents the interaction with most tetracyclines except doxycycline. Due to extensive enterohepatic cycling, iron binding may occur with doxycycline even when it is given parenterally. It has also been shown that when iron is administered up to 11 hours after doxycycline, serum concentrations of doxycycline may still be reduced by 20% to 45%.

MANAGEMENT: Coadministration of a tetracycline with any iron-containing product should be avoided if possible. Otherwise, patients should be advised to stagger the times of administration by at least three to four hours, although separating the doses may not prevent the interaction with doxycycline.

References

  1. Neuvonen PJ (1976) "Interactions with the absorption of tetracyclines." Drugs, 11, p. 45-54
  2. Gothoni G, Neuvonen PJ, Mattila M, Hackman R (1972) "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand, 191, p. 409-11
  3. Venho VM, Salonen RO, Mattila MJ (1978) "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol, 14, p. 277-80
  4. (2002) "Product Information. Minocin (minocycline)." Lederle Laboratories
  5. Campbell NR, Hasinoff BB (1991) "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol, 31, p. 251-5
  6. Bateman FJ (1970) "Effects of tetracyclines." Br Med J, 4, p. 802
  7. Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K (1970) "Interference of iron with the absorption of tetracyclines in man." Br Med J, 4, p. 532-4
  8. Greenberger NJ (1971) "Absorption of tetracyclines: interference by iron." Ann Intern Med, 74, p. 792-3
  9. Neuvonen PJ, Penttila O (1974) "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol, 7, p. 361-3
  10. (2018) "Product Information. Seysara (sarecycline)." Allergan Inc
  11. (2018) "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.
View all 11 references

Switch to consumer interaction data

Minor

doxycycline food

Applies to: Periostat (doxycycline)

Chronic alcohol consumption may enhance the elimination of doxycycline. The mechanism is induction of hepatic microsomal enzymes by alcohol. In one study, the half-life of doxycycline in six alcoholics was 10.5 hours, compared with 14.7 hours in six control patients. In addition, half the alcoholic patients had serum concentrations below what is generally considered the minimum therapeutic concentration (0.5 mcg/mL) at 12 to 24 hours after the dose. The investigators suggest that twice-a-day dosing may be indicated in these patients, especially if additional inducing drugs are used. The elimination of other tetracyclines probably is not affected by alcohol consumption.

References

  1. Neuvonen PJ, Penttila O, Roos M, Tirkkonen J (1976) "Effect of long-term alcohol consumption on the half-life of tetracycline and doxycycline in man." Int J Clin Pharmacol Biopharm, 14, p. 303-7

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.